US Patent

US10183931 — Rho kinase inhibitors

Method of Use · Assigned to Kadmon Corp LLC · Expires 2033-10-07 · 7y remaining

Vulnerability score 62/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects methods of treating diseases and disorders by inhibiting ROCK1 and/or ROCK2 using rho kinase inhibitors.

USPTO Abstract

The invention relates to inhibitors of ROCK1 and/or ROCK2. Also provided are methods of treating diseases and disorders involving inhibiting ROCK1 and/or ROCK2.

Drugs covered by this patent

belumosudil-mesylate (BELUMOSUDIL MESYLATE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-4260`	—	belumosudil-mesylate

Patent Metadata

Patent number: US10183931
Jurisdiction: US
Classification: Method of Use
Expires: 2033-10-07
Drug substance claim: No
Drug product claim: No
Assignee: Kadmon Corp LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.